Latest filings (excl ownership)
CT ORDER
Confidential treatment order
1 Jun 15
15-12B
Securities registration termination
18 May 15
UPLOAD
Letter from SEC
14 May 15
25-NSE
Exchange delisting
7 May 15
8-K
Completion of Acquisition or Disposition of Assets
7 May 15
RW
Registration withdrawal request
7 May 15
S-8 POS
Registration of securities for employees (post-effective amendment)
7 May 15
S-8 POS
Registration of securities for employees (post-effective amendment)
7 May 15
S-8 POS
Registration of securities for employees (post-effective amendment)
7 May 15
S-8 POS
Registration of securities for employees (post-effective amendment)
7 May 15
SC 14D9/A
Tender offer solicitation (amended)
7 May 15
SC TO-T/A
Third party tender offer statement (amended)
7 May 15
10-Q
2015 Q1
Quarterly report
6 May 15
SC 14D9/A
Tender offer solicitation (amended)
30 Apr 15
SC TO-T/A
Third party tender offer statement (amended)
30 Apr 15
10-K/A
2014 FY
Annual report (amended)
29 Apr 15
SC TO-T/A
Third party tender offer statement (amended)
27 Apr 15
CORRESP
Correspondence with SEC
22 Apr 15
SC 14D9/A
Tender offer solicitation (amended)
22 Apr 15
SC TO-T/A
Third party tender offer statement (amended)
22 Apr 15
UPLOAD
Letter from SEC
20 Apr 15
SC TO-T/A
Third party tender offer statement (amended)
14 Apr 15
8-K
Results of Operations and Financial Condition
9 Apr 15
8-K/A
Entry into a Material Definitive Agreement
9 Apr 15
SC 14D9
Tender offer solicitation
9 Apr 15
SC TO-C
Information about tender offer
9 Apr 15
SC TO-C
Information about tender offer
9 Apr 15
SC TO-T
Third party tender offer statement
9 Apr 15
SC TO-C
Information about tender offer
31 Mar 15
8-K
Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per share or $1.1 Billion in Cash
30 Mar 15
SC 14D9
Tender offer solicitation
30 Mar 15
SC TO-C
Information about tender offer
30 Mar 15
10-K
2014 FY
Annual report
4 Mar 15
8-K
UCD Product Portfolio Generates $113.6 Million for Fiscal Year 2014 and $30.8 Million in Net Sales During the Fourth Quarter of 2014
26 Feb 15
8-K
Hyperion Therapeutics Enters Into Completion of Phase III Clinical Trial, Option and Mutual Release
17 Feb 15
8-K
Departure of Directors or Certain Officers
10 Feb 15
S-8
Registration of securities for employees
21 Jan 15
10-Q
2014 Q3
Quarterly report
6 Nov 14
8-K
Results of Operations and Financial Condition
6 Nov 14
CT ORDER
Confidential treatment order
10 Oct 14
Latest ownership filings
SC 13G/A
Hyperion Therapeutics Inc
11 Feb 16
SC 13D/A
Hyperion Therapeutics Inc
15 May 15
4
Change in insider ownership
11 May 15
4
M JAMES BARRETT
11 May 15
4
Jason Raleigh Nunn
11 May 15
4
FOREST BASKETT
11 May 15
4
PATRICK J KERINS
11 May 15
4
SCOTT D SANDELL
11 May 15
4
RYAN D DRANT
11 May 15
4
KRISHNA KITTU KOLLURI
11 May 15
4
PETER J BARRIS
11 May 15
SC 13D/A
Beneficial ownership report (amended)
11 May 15
4
Bijan Salehizadeh
8 May 15
4
Ashley C. Gould
8 May 15
4
Bo Jesper Hansen
8 May 15
4
Theodore R Schroeder
8 May 15
4
Christine A Nash
8 May 15
4
Lota S. Zoth
8 May 15
4
JAMES HEALY
8 May 15
4
Jeffrey S Farrow
8 May 15
4
Natalie C. Holles
8 May 15
4
Bruce Frederick Scharschmidt
8 May 15
4
DANIEL G WELCH
8 May 15
4
Donald J Santel
8 May 15
4
MICHAEL POWELL
8 May 15
4
Donald J Santel
5 May 15
4
Bruce Frederick Scharschmidt
5 May 15
4
Jeffrey S Farrow
5 May 15
4
Christine A Nash
5 May 15
SC 13D
Hyperion Therapeutics Inc
23 Apr 15
SC 13G/A
Hyperion Therapeutics Inc
10 Apr 15
SC 13D/A
Beneficial ownership report (amended)
7 Apr 15
SC 13D/A
Hyperion Therapeutics Inc
3 Apr 15
4
Christine A Nash
17 Mar 15
4
Christine A Nash
13 Mar 15
SC 13D/A
Hyperion Therapeutics Inc
12 Mar 15
4
Christine A Nash
10 Mar 15
SC 13D/A
Hyperion Therapeutics Inc
10 Mar 15
SC 13G
Hyperion Therapeutics Inc
17 Feb 15
SC 13G/A
Hyperion Therapeutics Inc
13 Feb 15